SCM
RGNX icon

Silverarc Capital Management’s Regenxbio RGNX Stock Holding History

Silverarc Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-110,085
Closed -$2.91M – 100
2022
Q3 		$2.91M Buy
110,085
+5,956
+6% +$177K 0.98% 34
2022
Q2 		$2.57M Buy
+104,129
New +$2.6M 0.79% 35

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Silverarc Capital Management's RGNX Position: Q4 2022 in Review

Silverarc Capital Management sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 110,085 shares — an estimated $2.91M sold.

Silverarc Capital Management first reported a position in RGNX in Q2 2022 and held it in 2 quarters. The position peaked at $2.91M in Q3 2022. 182 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Silverarc Capital Management reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 110,085 Regenxbio shares in Q4 2022, an estimated $2.91M.
  • Silverarc Capital Management first reported a position in Regenxbio in Q2 2022 and held it in 2 quarters.
  • Silverarc Capital Management's Regenxbio position peaked at $2.91M in Q3 2022.
  • 182 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.